JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus

Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients

(2016) Christine Braegelmann et al.   EXPERIMENTAL DERMATOLOGY

JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus

(2016) Joerg Wenzel et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Advances in the treatment of cutaneous lupus erythematosus

(2016) A Kuhn et al.   LUPUS

Topical Ruxolitinib for the Treatment of Alopecia Universalis

(2016) Brittany G. Craiglow et al.   JAMA Dermatology

Upcoming therapeutic targets in cutaneous lupus erythematous

(2016) Anna Sophie Klaeschen et al.   Expert Review of Clinical Pharmacology

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms

(2015) Kathrin Schönberg et al.   CANCER RESEARCH

Correction to: “ Journal of Investigative Dermatology ” advance online publication, 9 April 2015; doi:10.1038/jid.2015.107

(2015) Emilie S. Chan et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib

(2014) Thorsten Hornung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Jakpot! New small molecules in autoimmune and inflammatory diseases

(2013) Kamran Ghoreschi et al.   EXPERIMENTAL DERMATOLOGY